|
Saturday, June 24 |
|
6:00 PM |
Conference Registration |
|
|
8:00 PM |
Welcome Reception and Dinner |
|
|
Sunday, June 25 |
|
8:00 AM |
Breakfast |
|||||
|
SESSION I |
Neurological, Ocular & Lysosomal Storage Diseases Chairs: Kip Connor and Andrea Tenner |
|||||
|
9:00 AM |
1 |
How complement eliminates synapses in development and disease Beth Stevens |
||||
|
9:20 AM |
2 |
Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss Andrea Tenner and Michael Hernandez |
||||
|
9:40 AM |
3 |
Targeting the lectin complement pathway in brain disorders Maria-Grazia De Simoni |
||||
|
10:00 AM |
4 |
Neuroprotective role of complement inhibition in retinal degeneration Kip Connor |
||||
|
10:20 AM |
5 |
Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease Joerg Koehl, Manoj Pandey, Thomas Burrow, Reena Rani, Lisa Martin, David Witte, Kenneth Setchell, Mary McKay, Albert Magnusen, Wujuan Zhang, Benjamin Liou, and Gregory Grabowski |
||||
|
Beyond Discovery I |
||||||
|
10:40 AM |
6 |
How will BREXIT and the new Unitary Patent System affect patents in Europe? Janet Reed |
||||
|
10:55 AM |
Coffee Break & Poster Viewing |
|||||
|
SESSION II |
Complement in Cancer Progression & Therapy Chairs: Edimara Reis and Ronald Taylor |
|||||
|
11:40 AM |
7 |
Complement and humoral innate immunity in the regulation of cancer-related inflammation Alberto Mantovani |
||||
|
12:00 PM |
8 |
Complement in cancer: untangling an intricate relationship Edimara Reis |
||||
|
12:20 PM |
9 |
Looking at cell surface expressed C1q through a different prism: a potential target for cancer therapy? Berhane Ghebrehiwet, Evelyn Kandov, Daniel Irizarry, Uday Kishore, and Ellinor Peerschke |
||||
|
12:40 PM |
10 |
Premetastatic pneumonia. Unrecognized disease - a new target for anticancer therapy Maciej Markiewski and Magdalena Karbowniczek |
||||
|
1:00 PM |
11 |
Compelling evidence for re-design of dosing schedules in mAb-based immunotherapy of cancer: Lessons learned from CD20 mAbs Ronald Taylor and Margaret Lindorfer |
||||
|
1:20 PM |
12 |
Complement-fed immune stimulatory vicious cycle: a safety issue in nano-bio-pharmacotherapy Janos Szebeni |
||||
|
1:40 PM |
Lunch and Informal Discussions |
|||||
|
7:30 PM |
Dinner and Informal Discussions |
|||||
|
Monday, June 26 |
|
8:00 AM |
Breakfast |
|||
|
SESSION III |
Targerting Diseases at the Terminal Pathway Level Chairs: Joerg Koehl and Christoph Schmidt |
|||
|
9:00 AM |
13 |
C5 inhibition: News about eculizumab for refractory generalized Myasthenia Gravis (gMG) and ALXN1210 Camille Bedrosian and on behalf of the Alexion refractory gMG and ALXN1210 teams and participating investigators and patients |
||
|
9:20 AM |
14 |
Mechanistic insight into C5 activation reveals limitations of therapeutic C5 inhibitors and illustrates how those can be overcome Christoph Schmidt and Markus Harder |
||
|
9:40 AM |
15 |
Role of complement membrane attack complex in sepsis Peter Ward, Fatemeh Fattahi, Firas Zetoune, Wenchao Song, B. Paul Morgan, and Michael Matthay |
||
|
10:00 AM |
16 |
Mechanistic insights into terminal pathway activation in osteoarthritis Jo Bramhall, Christina Bessant, Isabelle Osuch, Amy Dawson, Karen Miller, Kathy Triantafilou, and Eva-Maria Nichols |
||
|
10:15 AM |
17 |
C5aR1 as a target to suppress the development and pathogenicity of autoantibodies in experimental epidermolysis bullosa acquisita Christian Karsten, Kristin Schröder, Ania Kordowski, Balint Kovacs, Ralf Ludwig, and Jörg Köhl |
||
|
Beyond Discovery II |
||||
|
10:30 AM |
18 |
Funding Translational Research and Development of Pharmaceutical Innovation - Sources and Strategies to Create Novel Therapeutics Charles Baltic III |
||
|
10:50 AM |
Coffee Break & Poster Viewing |
|||
|
SESSION IV |
Molecular, Physiological & Pathophysiological Mechanisms Chairs: Piet Gros and Lubka Roumenina |
|||
|
11:30 AM |
19 |
Structural insights into complement activation and regulation Piet Gros |
||
|
11:50 AM |
20 |
“The C3 tickover” studied with S77, an antibody that inhibits it Peter Lachmann, Elizabeth Lay, David Seilly, and Menno Van Lookeren Campagne |
||
|
12:10 PM |
21 |
Hemolysis drives particular susceptibility of glomerular endothelium to complement overactivation. Olivia May, Nicolas Merle, Anne Grunenwald, Helena Rajaratnam, Samantha Knockaert, Jordan Dimitrov, Veronique Fremeaux-Bacchi, Marie Frimat, and Lubka Roumenina |
||
|
12:30 PM |
22 |
Orphan complement activation fragment C4a as a novel untethered agonist mediates effector functions through binding to protease-activated receptor (PAR) 1 and 4 Hongbin Wang, Daniel Ricklin, and John Lambris |
||
|
12:45 PM |
23 |
Functional characterization of alternative pathway C3 and C5 convertase inhibitors Ronald Gorham Jr., Seline Zwarthoff, Xiaoguang Xue, Maartje Ruyken, Mihály Józsi, Piet Gros, and Suzan Rooijakkers |
||
|
1:00 PM |
24 |
Carboxypeptidase N and Procarboxypeptidase B2 play complementary and non-redundant roles in the protection against anaphylatoxins and inflammatory mediators Lawrence Leung and John Morser |
||
|
1:20 PM |
25 |
Functional and structural insights into properdin control of the complement alternative pathway Dennis Pedersen, Lubka Roumenina, Rasmus Jensen, Trine Gadeberg, Chiara Marinozzi, Capucine Picard, Tania Rybkine, Steffen Thiel, Uffe Sørensen, Cordula Stover, Veronique Fremeaux‐Bacchi, and Gregers Andersen |
||
|
1:35 PM |
Lunch and Informal Discussions |
|||
|
7:30 PM |
Dinner and Informal Discussions |
|||
|
Tuesday, June 27 |
|
8:00 AM |
Breakfast |
|
|
SESSION V |
Kidney Diseases, I/R Injury & Transplantation Chairs: Charles Baltic and Alireza Biglarnia |
|
|
9:00 AM |
26 |
Precision medicine for C3 Glomerulopathy Richard Smith |
|
9:20 AM |
27 |
C3 and C5 nephritic factors in C3 Glomerulopathies Veronique Fremeaux-Bacchi |
|
9:40 AM |
28 |
The mystery of “Glomerulonephritis with dominant C3 deposition” Carla Nester |
|
10:00 AM |
29 |
Alternative pathway or alternative view on renal ischemia reperfusion injury Cees van Kooten |
|
10:20 AM |
30 |
Efficacy and safety of Cp40 to reduce ischemia reperfusion injury in non-human primates Alireza Biglarnia, Frank Zoerner, Edimara Reis, Daniel Ricklin, Ranillo Resuello, Joel Tuplano, Bo Nilsson, Martijn van Griensven, Markus Huber-Lang, and John Lambris |
|
10:40 AM |
31 |
Protection against thromboinflammation in kidney transplantation using a PEG-phospholipid construct Bo Nilsson |
|
11:00 AM |
32 |
TBA Robert Montgomery |
|
11:20 AM |
Coffee Break & Poster Viewing |
|
|
SESSION VI |
Targerting Diseases at the Initiation/Amplification Level Chairs: Daniel Ricklin and Carl Atkinson |
|
|
11:40 AM |
33 |
Compstatin Cp40 (AMY-101): a C3-targeted complement inhibitor reaching its prime for bedside intervention John D Lambris, Edimara Reis, Daniel Ricklin, Nadja Berger, Tchilabalo Alayi, Georgia Sfyroera, Hongbin Wang, Markus Huber-Lang,Bo Nilsson, Kristina Nilsson-Ekdahl, Richard J Smith, Carla Nester, Meryl Waldman, Dimitrios Mastellos, Margaret A Lindorfer, Ronald P Taylor, Piet Gros, George Hajishengallis, Lorraine M Rusch, Elias Sayias, Margarita Nunez, Despina Yancopoulou, and Antonio M Risitano |
|
12:00 PM |
34 |
Complement and periodontitis: the role of the alternative pathway George Hajishengallis, Xiaofei Li, Tetsuhiro Kajikawa, Evlambia Hajishengallis, Edimara Reis, and John Lambris |
|
12:20 PM |
35 |
Interconnections and key roles of alternative and lectin pathway components in the pathogenesis of experimental rheumatoid arthritis Nirmal Banda, Robert Scheinman, Wuding Zhou, Conrad Farrar, Steven Sacks, Steffen Thiel, Yuichi Endo, Teijo Fujita, Hideharu Sekine, and Michael Holers |
|
12:40 PM |
36 |
Role of complement activation in hemorrhagic shock – protection by C3 Blockade Markus Huber-Lang, Ranillo Resuello, Joel Tuplano, Sofia Koutsogiannaki, Alexandra Primikyri, Edimara Reis, Kristina Nilsson, Bo Nilsson, Daniel Ricklin, John Lambris, and Martijn van Griensven |
|
1:00 PM |
37 |
Systemic- and local complement activation controls the NLRP3 inflammasome pathway in patients with atherosclerosis Nathalie Niyonzima, Siril Bakke, Bente Halvorsen, Ida Gregersen, Mona Skjelland, Arne Yndestad, Øystein Sandanger, Geir Andersen, Lars Gullestad, Eicke Latz, Pål Aukrust, Tom Mollnes, and Terje Espevik |
|
1:20 PM |
38 |
Inhibitors of the alternative complement may have lower infection risks than anti-C5 treatments Anna Schubart |
|
1:35 PM |
Lunch and Informal Discussions |
|
|
3:00 PM |
City Tour |
|
|
7:30 PM |
Dinner and Informal Discussions |
|
|
Wednesday, June 28 |
|
8:00 AM |
Breakfast |
|
|
SESSION VII |
Hemolytic & Pulmonary Diseases Chairs: Antonio Risitano and Sacha Zeerleder |
|
|
9:00 AM |
39 |
Progresses in clinical development of novel complement inhibitors for PNH: Question (and answers?) Antonio Risitano |
|
9:20 AM |
40 |
Targeting complement to treat paroxysmal nocturnal hemoglobinuria (PNH) Rodrigo Calado |
|
9:40 AM |
41 |
Intra and extra vascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH): a never-ending hike between beds and benches Rosario Notaro |
|
10:00 AM |
42 |
The effect of complement inhibition on erythrocyte destruction in AIHA I Baas, Edimara Reis, John Lambris, M de Haas, D Wouters, and Sasha Zeerleder |
|
10:20 AM |
43 |
Complement therapeutics in cigarette smoke induced emphysema development and progression Sarah Stephenson, Ali Alawieh, Andrew Kirst, Stephen Tomlinson, and Carl Atkinson |
|
10:40 AM |
44 |
Cigarette smoke impairs complement-mediated phagocytosis of Streptococcus pneumoniae in patients with chronic obstructive pulmonary disease allowing persistent infection in the respiratory tract Leire Aguinagalde, Carmen Ardanuy, Josefina Liñares, Ernesto García, and Jose Yuste |
|
10:55 AM |
45 |
Complement inhibition in brain dead donors mitigates post-lung transplantation inflammation and injury in a murine model Kunal Patel, Qi Cheng, Biao Lei, Daniel Allen, Timothy Whelan, Martin Goddard, Stephen Tomlinson, Satish Nadig, and Carl Atkinson |
|
11:10 AM |
Coffee Break & Poster Viewing |
|
|
Beyond Discovery III |
||
|
11:50 AM |
46 |
The University Center for Innovation Model John Swartley |
|
SESSION VIII |
Diagnostics & Biomarkers Chairs: Anna Blom and Tom Mollnes |
|
|
12:10 PM |
47 |
Complement analyses: new concepts in the era of complement inhibitory therapy in the clinic Tom Mollnes |
|
12:30 PM |
48 |
Optimization of complement functional assays for the testing of complement inhibitory therapeutics Ashley Frazer-Abel, Thuy Ton, Delphine El Mehdi, Carolina Vega, and Pascal Deschatelets |
|
12:45 PM |
49 |
Novel assay for measurement of plasma C4d levels Marcin Okroj, Myriam Martin, Daniel Ajona, Anders Bengtsson, Ruben Pio, and Anna Blom |
|
1:05 PM |
50 |
Further studies on C1q as a biomarker of disease activity in SLE Kristina Ekdahl |
|
1:20 PM |
51 |
Proteomic analysis of gingival crevicular fluid from non-human primates locally treated with the complement inhibitor Cp40 Nagihan Bostanci, Kai Bao, Li Li Xiaofei, Tomoki Maekawa, Jonas Grossmann, George Belibasakis, John Lambris, and George Hajishengallis |
|
1:35 PM |
52 |
Simultaneous monitoring of multiple complement activation markers: development of rapid, point-of-care assays for sC5b9 and C4d and proof of concept in the hemodialysis clinic setting Nick Staten, W Schaiff, Adrienne Clagettt, Jacklyn Kesler, Junhan Wang, Jennifer Ritchie, Ashley Anderson, Brigitta Brannon, Charles Ellis, Talat Ikizler, and Martin Schmidt |
|
1:50 PM |
Lunch and Informal Discussions |
|
|
8:00 PM |
Farewell Dinner |
|
|
|||||||||||||||||||||||||||||||
|
POSTERS |
|
|
53 |
Complement and periodontitis: the role of the classical pathway Tetsuhiro Kajikawa, Edimara Reis, John Lambris, and George Hajishengallis |
|
54 |
Intracellular complement activation involves in liver damage of Trichloroethylene-sensitized BALB/c mice Yun Yu, Xiao-Dong Yang, Jia-Xiang Zhang, Tong Shen, and Qixing Zhu |
|
55 |
Poly(I:C) aggravates immunological liver injury in mouse model of trichloroethylene sensitization Tong Shen, Cheng Zhang, Jia-Xiang zhang, and Qixing Zhu |
|
56 |
Roles for the N-terminal, C-terminal and Y402H polymorphism of CFH in an experimental model for neovascular age-related macular degeneration: differential effects on complement, inflammation and oxidative stress Céline Borras, Kimberley Delaunay, Sylvie Jorieux, Toufik Abache, Marie-Christine Naud, Alexandre Sellam, Mohamed El Sanharawi, NA AN, Emmanuelle Gelizé, Patricia Lassiaz, Francine Bahar-Cohen, Frederic Mascarelli, and Virginie Dinet |
|
57 |
Humanised mouse properdin could augment the alternative pathway of wild type mouse and normal human sera on zymosan and Plasmodium falciparum merozoites coated plate. Mohenned Alsaadawi and Nicholas Lynch |
|
58 |
The relationship between Eculizumab concentration, Eculizumab-C5 complexes, C5 concentration and complement hemolytic activity Maarten Oranje, Diana Wouters, Frederike Bemelman, and Kyra Gelderman |
|
59 |
Complement therapeutics for prevention of PF4/heparin antibodies Sanjay Khandelwal and Gowthami Arepally |
|
60 |
Delineation of mechanisms for evasion of complement deposition by Burkholderia pseudomallei Laura Stansbury, Minal Mulye, Michael Woodman, and R. Wooten |
|
61 |
In vitro testing as an effective way to evaluate therapeutics for complement inhibition or activation Jaclyn Dennis, Carter Reid, Erin Archuleta, Matthew Eggleston, Dana Le, Roza Mkonu, Linda Remigio, and Vijaya Knight |
|
62 |
Evaluation of mechanisms of paroxysm in paroxysmal nocturnal hemoglobinuria: “Bystander Hemolysis” vs. perturbation of soluble regulators Mingjun Huang, Jane Thanassi, Manuel Galvan, Guangwei Yang, Xuan Yuan, Yongsen Zhao, Dharaben Patel, Joanne Fabrycki, Amanda Luu, Wengang Yang, Steven Podos, Joel Barrish, and Robert Brodsky |
|
63 |
Repression of C1QBP is a prerequisite of pathologic cardiac hypertrophy Eman Hagag, Božena Kesić, and Peter Mirtschink |
|
64 |
A rapid assay for the determination of ADAMTS-13 activity Nikolaus Binder, Margaret Griffiths, Helga Vetr, Kyle Zingaro, Patricia Bento, and Susan Faas |
|
65 |
Generation of CD46, CD55 and CD59 CRISPR/Cas9 knockout cell lines Darren Gormley, Katie West, Tara Busiau, Lisa Spatt, Richard Priest, Karen Miller, and Eva-Maria Nichols |
|
66 |
Development of iC3b and full length factor B immunoassays Christina Bessant, Darren Gormley, Marta Biedzka-Sarek, Karen Miller, and Eva-Maria Nichols |
|
67 |
Genetic landscape of aHUS – a comprehensive analysis of genetic variants reported in literature Rui-Ru Ji, Tatiana Serebriyskaya, and Natalia Kuzkina |